- Home
- HTO vs TARS Comparison
HTO vs TARS Comparison
Compare HTO & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTO
- TARS
- Stock Information
- Founded
- HTO 1985
- TARS 2016
- Country
- HTO United States
- TARS United States
- Employees
- HTO N/A
- TARS N/A
- Industry
- HTO Water Supply
- TARS Medicinal Chemicals and Botanical Products
- Sector
- HTO Utilities
- TARS Health Care
- Exchange
- HTO Nasdaq
- TARS Nasdaq
- Market Cap
- HTO 1.8B
- TARS 1.7B
- IPO Year
- HTO N/A
- TARS 2020
- Fundamental
- Price
- HTO $50.45
- TARS $44.08
- Analyst Decision
- HTO
- TARS Strong Buy
- Analyst Count
- HTO 0
- TARS 7
- Target Price
- HTO N/A
- TARS $67.14
- AVG Volume (30 Days)
- HTO 232.7K
- TARS 566.6K
- Earning Date
- HTO 07-28-2025
- TARS 08-07-2025
- Dividend Yield
- HTO 3.35%
- TARS N/A
- EPS Growth
- HTO 12.16
- TARS N/A
- EPS
- HTO 2.98
- TARS N/A
- Revenue
- HTO $766,656,000.00
- TARS $233,674,000.00
- Revenue This Year
- HTO $6.23
- TARS $122.94
- Revenue Next Year
- HTO $5.34
- TARS $44.14
- P/E Ratio
- HTO $16.83
- TARS N/A
- Revenue Growth
- HTO 12.34
- TARS 449.03
- 52 Week Low
- HTO $44.91
- TARS $20.08
- 52 Week High
- HTO $62.18
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- HTO N/A
- TARS 60.29
- Support Level
- HTO N/A
- TARS $39.11
- Resistance Level
- HTO N/A
- TARS $41.70
- Average True Range (ATR)
- HTO 0.00
- TARS 1.55
- MACD
- HTO 0.00
- TARS 0.44
- Stochastic Oscillator
- HTO 0.00
- TARS 94.89
About HTO H2O America Common Stock
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.